{"url":"https://lda.senate.gov/api/v1/filings/227fc207-e608-446c-aa5c-e9903743b619/","filing_uuid":"227fc207-e608-446c-aa5c-e9903743b619","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2008,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/227fc207-e608-446c-aa5c-e9903743b619/print/","filing_document_content_type":"text/html","income":null,"expenses":"150000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Nicholas P. Wise, Senior Vice President","dt_posted":"2008-11-06T12:50:39-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"444 North Capitol Street NW","registrant_address_2":"Suite 821","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":40030261,"url":"https://lda.senate.gov/api/v1/registrants/40030261/","house_registrant_id":39870,"name":"PRASCO","description":"Generic pharmaceutical distributer","address_1":"444 North Capitol Street NW","address_2":"Suite 821","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"NICHOLAS WISE","contact_telephone":"","dt_updated":"2022-04-06T16:07:38.817870-04:00"},"client":{"id":188243,"url":"https://lda.senate.gov/api/v1/clients/188243/","client_id":12,"name":"PRASCO","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"OH","state_display":"Ohio","country":"US","country_display":"United States of America","ppb_state":null,"ppb_state_display":null,"ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2008-01-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Authorized Generics generally\nFTC study of Authorized Generics\nCMS regulations implementing DRA","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":40394,"prefix":null,"prefix_display":null,"first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"WISE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":42095,"prefix":null,"prefix_display":null,"first_name":"TRICIA","nickname":null,"middle_name":null,"last_name":"WISE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":64,"name":"Federal Trade Commission (FTC)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}